公开(公告)号：WO2007080123A1

公开(公告)日：2007-07-19

申请号：PCT/EP2007/000272

申请日：2007-01-12

Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC. ,  KOST, Holger

Inventor： KOST, Holger

IPC: G01N33/569 ,  C12N7/02

CPC classification number: C12Q3/00 ,  C12N7/00 ,  C12N2760/16011 ,  C12N2760/16111 ,  C12N2760/16211 ,  C12Q1/04 ,  G01N33/56983 ,  G01N2333/07 ,  G01N2333/11

Abstract: The invention provides a method for determining the concentration of virus particles and/or virus antigens in a sample. In particular, the invention relates to determining the concentration of influenza virus particles/influenza virus antigens in a sample. The invention further relates to the use of an ion-exchange matrix for the determination of the concentration of virus particles and/or virus antigens in a sample.

Abstract translation: 本发明提供了一种确定样品中病毒颗粒和/或病毒抗原浓度的方法。 特别地，本发明涉及确定样品中流感病毒颗粒/流感病毒抗原的浓度。 本发明还涉及离子交换基质用于测定样品中病毒颗粒和/或病毒抗原浓度的用途。

公开(公告)号：WO2009118420A9

公开(公告)日：2009-10-01

申请号：PCT/EP2009/053698

申请日：2009-03-27

Applicant: NOVARTIS AG ,  KOST, Holger ,  RAMSEGER, Simon

Inventor： KOST, Holger ,  RAMSEGER, Simon

IPC: G01N27/447

Abstract: The present invention relates to a method for detecting nucleic acids, wherein a sample to be analyzed for the presence of nucleic acids is separated by capillary electrophoresis. The conditions of sample injection and separation allow for an extremely high sensitivity of the method, which can be applied, e.g. for quality control purposes in the determination or the presence, quantity and/or size of genomic DNA contaminants in samples comprising proteins for therapy or vaccination.

公开(公告)号：WO2007085969A2

公开(公告)日：2007-08-02

申请号：PCT/IB2007/001150

申请日：2007-01-26

Applicant: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG ,  BROEKER, Michael ,  KOST, Holger

Inventor： BROEKER, Michael ,  KOST, Holger

CPC classification number: A61K39/145 ,  A61K39/12 ,  A61K2039/55566 ,  A61K2039/70 ,  C07K14/005 ,  C12N7/00 ,  C12N2760/16122 ,  C12N2760/16134 ,  C12N2760/16151 ,  C12N2760/16171 ,  C12N2760/16222 ,  C12N2760/16234

Abstract: An immunogenic composition comprising influenza virus haemagglutinin and matrix proteins. These may be from influenza viruses grown in cell culture rather than eggs. The matrix protein may be a fragment of a full-length viral matrix protein e.g. a matrix M1 fragment with a molecular weight of less than 2OkDa. The composition may be a subunit vaccine comprising purified surface glycoproteins.

Abstract translation: 包含流感病毒血细胞凝集素和基质蛋白的免疫原性组合物。 这些可能来自细胞培养中生长的流感病毒而不是卵子。 基质蛋白可以是全长病毒基质蛋白的片段，例如 分子量小于20kDa的基质M1片段。 该组合物可以是包含纯化表面糖蛋白的亚单位疫苗。

公开(公告)号：WO2007052163A3

公开(公告)日：2007-05-10

申请号：PCT/IB2006/003880

申请日：2006-11-01

Applicant: NOVARTIS VACCINES AND DIAGNOSTICS GMBH & CO KG ,  GREGERSEN, Jens-Peter ,  KOST, Holger

Inventor： GREGERSEN, Jens-Peter ,  KOST, Holger

IPC: A61K39/12 ,  A61K39/145

Abstract: The present invention relates to vaccine products for the treatment or prevention of viral infections. Further provided are methods of reducing contaminants associated with the preparation of cell culture vaccines. Residual functional cell culture DNA is degraded by treatment with a DNA alkylating agent, such as β-propiolactone (BPL), thereby providing a vaccine comprising immunogenic proteins derived from a virus propagated on cell culture, substantially free of residual functional cell culture DNA.